Zentalis Pharmaceuticals, Inc. (ZNTL) Form 8-K — May 27, 2026
Zentalis Pharmaceuticals, Inc. appointed Shannon Campbell as a Class I director, effective May 22, 2026, increasing the board size from six to seven members. Ms. Campbell was also appointed to the Compensation Committee and received an initial grant of 114,200 restricted stock units vesting over three years.
Key figures
- Initial rsu grant
- 114200
- Annual grant formula pct
- 0.08
- Annual board retainer usd
- 45000
- Initial grant formula pct
- 0.16
- Compensation committee retainer usd
- 7500
Price after filing
1 day: +0.7%7 days: -7.5%30 days: -5.7%
Close on the filing date to close N calendar days later (from $4.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.